Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.77 |
| ▸ | KLK1 | P06870 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6803670 | 0.88 | F10 (0.79) | F10KLK1KCNH2 | |
| SCHEMBL6801431 | 0.87 | F10 (1.00) | F10KLK1KCNH2 | |
| SCHEMBL6807872 | 0.82 | F10 (0.55) | F10KLK1MEN1KMT2ACYP3A4 | |
| SCHEMBL6807870 | 0.82 | F10 (0.55) | F10KLK1MEN1KMT2ACYP3A4 | |
| SCHEMBL6807283 | 0.81 | F10 (0.77) | F10KLK1KCNH2 | |
| SCHEMBL6807287 | 0.78 | F10 (0.71) | F10KLK1KCNH2 | |
| SCHEMBL6804050 | 0.76 | F10 (0.72) | F10KLK1KCNH2 | |
| SCHEMBL6807886 | 0.76 | F10 (0.75) | F10KLK1 | |
| SCHEMBL8175554 | 0.74 | F10 (0.74) | F10KLK1MEN1KMT2A | |
| SCHEMBL6803352 | 0.74 | F10 (0.72) | F10KLK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082786-A1 | Piperazine based inhibitors of factor xa | MILENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082786-A1 | Piperazine based inhibitors of factor xa | TFPI, F11, F12 | F10 11/4885KLK1 603/4885KCNH2 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.